Phase 3 N=407 Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=105 Mepolizumab in Nasal Polyposis
Nasal Polyps
Primary: Number of Participants With a Reduced Need for Surgery at Week 25 — 16; 5; 33; 46 Participants — p=0.003
N/A N=27 Qualitative Analysis of Subject Experience of Nasal Polyps
Nasal Polyps
Primary: Number of Participants Who Reported Primary Symptoms — 27; 27; 25; 24 Participants
N/A N=20 Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Phase 3 N=127 Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)
Nasal Polyps
Primary: Change From Baseline 24-hour Urinary Free Cortisol Level — 49.5; 39.6; 49.8; 1.5 mcg/hour — p=0.258
Phase 3 N=323 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Bilateral Nasal Polyposis
Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.26; -0.53; -0.56; -0.67 units on a scale
Phase 3 N=748 A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
Nasal Polyps
Primary: Change From Baseline in Congestion/Obstruction Score — -0.56; -0.42 score on a scale — p=0.0007
Phase 3 N=11 Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
Nasal Polyposis
Primary: Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video — -0.7 units on a scale
Phase 3 N=410 Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
Nasal Polyposis
Primary: Change From Baseline in Total NPS at Week 40 — -0.36; 0.17 Score on a scale — p=<0.0001
Phase 2 N=60 An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Nasal Polyps
Primary: Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16 — 5.67; 5.87; 5.39; 3.97 score on a scale — p=0.0009
Phase 2 N=27 Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis · Nasal Polyps
Primary: Objective (a) the Effect on Polypoid Mucosal Thickening in the Anterior Ethmoid and Maxillary Sinuses as Measured on Sinus CT Scan. — -8.9; 4.2 % Change
Phase 3 N=138 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — 0.06; -1.08 Score on a scale — p=<0.0001
Phase 2 N=24 Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Chronic Rhinosinusitis (Diagnosis) · Nasal Polyps · Eosinophilia
Primary: Change in Nasal Polyp Score — .9; .3 score on a scale
N/A N=37 The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
Chronic Sinusitis · Nasal Polyposis
Primary: Change in Lund-Kennedy Endoscopic Scores — -8.0; -1.5; -6.9 score on a scale
Phase 3 N=448 Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score — -0.38; -1.25 score on a scale — p=<0.0001
Phase 3 N=127 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — -0.31; -0.90 Score on a scale — p=0.0140
Phase 2 N=10 A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
Bilateral Nasal Polyposis
Primary: Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally) — -0.23; -0.99 score on a scale — p== 0.062
Phase 3 N=18 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
Phase 3 N=276 A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score — -0.45; -1.34 score on a scale — p=<0.0001
Phase 3 N=100 Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps
Chronic Sinusitis · Nasal Polyps
Primary: Nasal Obstruction/Congestion Score — 3.62; 3.30; 2.31; 2.62 units on a scale — p=0.1365
N/A N=32 Comparison of Nasal Steroids After FESS in CRSwNP
Sinusitis · Nasal Polyps
Primary: SNOT-22 Scores — 31.5; 10.29; 15.88 units on a scale
Phase 2 N=14 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
Rhinosinusitis · Chronic Polyposis
Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — -2; -0.8 units on a scale
Phase 2 N=40 Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
Nasal Polyposis
Primary: Change in Total Polys Score (TPS) — -0.5; -0.3; -0.2 score on a scale
Phase 3 N=332 Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
Chronic Rhinosinusitis
Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…
Phase 2 N=20 Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Primary: Ratio to Baseline in Peripheral Blood Eosinophil Counts After 6 Months of Treatment — 0.06 ratio to baseline — p=< 0.001
Phase 3 N=223 Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
Chronic Rhinosinusitis
Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…
Phase 3 N=408 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline in Total Nasal Polyp Score at Week 52 — -2.458; -0.380 Score — p=<.0001
Phase 4 N=34 Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)
Adenoids
Primary: Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score — 3.89; 1.26 Score on a scale
Phase 2 N=105 Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) to Week 16 — -0.87; -0.89; -0.49 score on a scale — p=0.2364
Phase 1 N=16 Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
Chronic Rhinosinusitis (Diagnosis)
Primary: Morning "AM" Serum Cortisol Level — 17.35; 14.48 mcg/dL